Loading
A phase 3 trial testing UGN-103 in bladder & urothelial cancer, active and no longer recruiting.
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer is a phase 3 interventional study registered as NCT06331299, led by UroGen Pharma, and active but no longer recruiting on the registry. Official title: A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low-grade (LG) Non-muscle Invasive Bladder Cancer (NMIBC) at Intermediate-risk (IR) of Recurrence. Planned enrolment is 99 participants (actual). The study started in 2024-08-29 and primary completion is expected in 2025-09-11. No results have been posted on ClinicalTrials.gov.
Shares UroGen Pharma, Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares UroGen Pharma, Bladder & urothelial cancer.
Shares UroGen Pharma, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer.